Drug Profile
Lasofoxifene - Sermonix Pharmaceuticals
Alternative Names: AZU-101; CP-336156; CP-336156-CB; Fablyn; Lasofoxifene tartrate; OporiaLatest Information Update: 29 Feb 2024
Price :
$50
*
At a glance
- Originator Ligand Pharmaceuticals; Pfizer
- Developer Eli Lilly and Company; Pfizer; Quantum Leap Healthcare Collaborative; Sermonix Pharmaceuticals
- Class Anti-inflammatories; Antineoplastics; Naphthalenes; Osteoporosis therapies; Pyrrolidines; Small molecules; Tetrahydronaphthalenes
- Mechanism of Action Cannabinoid receptor CB2 inverse agonists; Estrogen receptor alpha modulators; Estrogen receptor beta agonists; Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Breast cancer; HER2 negative breast cancer
- Preclinical Endometrial cancer
- Preregistration Submission Withdrawal Atrophic vaginitis; Postmenopausal osteoporosis
- No development reported Ovarian cancer
- Discontinued Hypogonadism
Most Recent Events
- 27 Feb 2024 Shanghai Henlius Biotech and Sermonix Pharmaceuticals plans to launch lasofoxifene for HER2-negative-breast-cancer in China
- 12 Feb 2024 Sermonix Pharmaceuticals a completes phase-II ELAINE 2 trials for Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT04432454)
- 12 Feb 2024 Sermonix Pharmaceuticals completes a phase II ELAINE 1 trial in Breast cancer (Late-stage disease, Metastatic disease, Monotherapy) in Canada, Israel (PO) (NCT03781063)